KR101464778B1 - 에티닐인돌 화합물 - Google Patents

에티닐인돌 화합물 Download PDF

Info

Publication number
KR101464778B1
KR101464778B1 KR1020090128213A KR20090128213A KR101464778B1 KR 101464778 B1 KR101464778 B1 KR 101464778B1 KR 1020090128213 A KR1020090128213 A KR 1020090128213A KR 20090128213 A KR20090128213 A KR 20090128213A KR 101464778 B1 KR101464778 B1 KR 101464778B1
Authority
KR
South Korea
Prior art keywords
compound
methyl
ethynyl
tlc
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020090128213A
Other languages
English (en)
Korean (ko)
Other versions
KR20100074036A (ko
Inventor
가즈유키 오모토
사토시 이타다니
요시스케 나카야마
준 다케우치
마나부 후지타
Original Assignee
오노 야꾸힝 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오노 야꾸힝 고교 가부시키가이샤 filed Critical 오노 야꾸힝 고교 가부시키가이샤
Publication of KR20100074036A publication Critical patent/KR20100074036A/ko
Application granted granted Critical
Publication of KR101464778B1 publication Critical patent/KR101464778B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
KR1020090128213A 2008-12-22 2009-12-21 에티닐인돌 화합물 Expired - Fee Related KR101464778B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JPJP-P-2008-325815 2008-12-22
JP2008325815 2008-12-22

Publications (2)

Publication Number Publication Date
KR20100074036A KR20100074036A (ko) 2010-07-01
KR101464778B1 true KR101464778B1 (ko) 2014-11-24

Family

ID=42110130

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020090128213A Expired - Fee Related KR101464778B1 (ko) 2008-12-22 2009-12-21 에티닐인돌 화합물

Country Status (18)

Country Link
US (1) US8115014B2 (enExample)
EP (1) EP2206698B1 (enExample)
JP (2) JP5012884B2 (enExample)
KR (1) KR101464778B1 (enExample)
CN (1) CN101759628B (enExample)
AU (1) AU2009250960C1 (enExample)
BR (1) BRPI0905601A2 (enExample)
CA (1) CA2688614C (enExample)
DK (1) DK2206698T3 (enExample)
ES (1) ES2387185T3 (enExample)
IL (1) IL202869A (enExample)
MX (1) MX2009013926A (enExample)
NZ (1) NZ582208A (enExample)
PL (1) PL2206698T3 (enExample)
PT (1) PT2206698E (enExample)
RU (1) RU2505531C2 (enExample)
TW (1) TWI469965B (enExample)
ZA (1) ZA200909096B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2803159A1 (en) * 2010-06-21 2011-12-29 Ono Pharmaceutical Co., Ltd. New crystalline forms of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid, and 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutano
KR101171790B1 (ko) 2010-07-30 2012-08-13 현대자동차주식회사 인출식 자전거 캐리어
PL2658844T3 (pl) 2010-12-28 2017-04-28 Sanofi Nowe pochodne pirymidyn, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT(pkb)
EP2537866A1 (en) * 2011-06-21 2012-12-26 Serumwerk Bernburg AG Hydroxyethyl starch derivatives, method for manufacturing the same and therapeutical uses thereof
CN103893146A (zh) * 2012-12-25 2014-07-02 天津药物研究院 含福多司坦缓释剂型
WO2020079652A1 (en) * 2018-10-17 2020-04-23 Insilico Medicine Hong Kong Limited Kinase inhibitors
EP4162952A4 (en) * 2020-04-30 2024-08-21 Kyoto University PROPHYLACTIC OR THERAPEUTIC AGENT FOR RNA VIRUS-RELATED DISEASES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965745A (en) 1995-10-10 1999-10-12 Pfizer Inc Indole carbamates as leukotriene antagonists
WO2004099192A2 (en) 2003-04-30 2004-11-18 The Institutes Of Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
EP1661892A1 (en) 2003-09-01 2006-05-31 Ono Pharmaceutical Co., Ltd. Condensed ring compound and use thereof
EP1852420A1 (en) * 2005-02-25 2007-11-07 Ono Pharmaceutical Co., Ltd. Indole compound and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (enExample) 1956-03-21 1900-01-01
US3095355A (en) 1961-10-12 1963-06-25 Revlon Aerosol composition
JPH01192476A (ja) 1988-01-25 1989-08-02 Kawasaki Steel Corp 溶接鋼管の製造方法
PT93943A (pt) 1989-05-05 1991-02-08 Searle & Co Processo para a preparacao de composicoes contendo compostos indole-2-carboxilato para tratamento de perturbacoes do snc
US5229413A (en) * 1989-05-05 1993-07-20 G. D. Searle & Co. Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
US5137910A (en) * 1989-05-05 1992-08-11 C.D. Searle & Co. Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
CA2019335C (en) 1989-06-27 2000-08-01 Mitoshi Konno Phenylalkan (en)oic acids
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
WO1994022821A1 (en) * 1993-04-05 1994-10-13 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives as testosterone 5 alpha-reductase inhibitors
FR2766824B1 (fr) * 1997-07-30 1999-09-10 Adir Nouveaux composes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9902455D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
WO2002000646A1 (en) 2000-06-27 2002-01-03 Smithkline Beecham Corporation Fatty acid synthase inhibitors
JP2003025362A (ja) 2001-07-18 2003-01-29 Nippon Tokushu Toryo Co Ltd 通気性を有する発泡プラスチック及びその製法
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
EP1515716A2 (en) 2002-04-03 2005-03-23 Astrazeneca AB Indole derivatives having anti-angiogenetic activity
EP1501796B1 (en) 2002-04-23 2007-05-09 Aventis Pharmaceuticals Inc. 3-(pyridinyl-amino)-1h-indole-2-carboxylic acid derivatives as interleukin-4 gene expression inhibitors
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965745A (en) 1995-10-10 1999-10-12 Pfizer Inc Indole carbamates as leukotriene antagonists
WO2004099192A2 (en) 2003-04-30 2004-11-18 The Institutes Of Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
EP1661892A1 (en) 2003-09-01 2006-05-31 Ono Pharmaceutical Co., Ltd. Condensed ring compound and use thereof
EP1852420A1 (en) * 2005-02-25 2007-11-07 Ono Pharmaceutical Co., Ltd. Indole compound and use thereof

Also Published As

Publication number Publication date
PT2206698E (pt) 2012-08-03
JP2010168359A (ja) 2010-08-05
AU2009250960A1 (en) 2010-07-08
US20100160647A1 (en) 2010-06-24
KR20100074036A (ko) 2010-07-01
MX2009013926A (es) 2010-06-22
DK2206698T3 (da) 2012-08-27
NZ582208A (en) 2011-05-27
CN101759628A (zh) 2010-06-30
EP2206698B1 (en) 2012-07-18
EP2206698A1 (en) 2010-07-14
BRPI0905601A2 (pt) 2012-05-02
PL2206698T3 (pl) 2012-12-31
AU2009250960B2 (en) 2013-09-05
RU2505531C2 (ru) 2014-01-27
CA2688614C (en) 2015-01-06
CA2688614A1 (en) 2010-06-22
ES2387185T3 (es) 2012-09-17
AU2009250960C1 (en) 2014-01-23
RU2009147506A (ru) 2011-06-27
TW201026664A (en) 2010-07-16
JP2012144546A (ja) 2012-08-02
CN101759628B (zh) 2013-02-27
ZA200909096B (en) 2010-09-29
US8115014B2 (en) 2012-02-14
TWI469965B (zh) 2015-01-21
JP5012884B2 (ja) 2012-08-29
IL202869A (en) 2015-02-26

Similar Documents

Publication Publication Date Title
RU2416601C2 (ru) Соединение индола и его применение
KR101464778B1 (ko) 에티닐인돌 화합물
EP0901470B1 (en) Indole derivatives useful as endothelin receptor antagonists
HUP0203524A2 (hu) Daganatellenes hatású 2- (1H-indol-3-il)-2-oxo-acetamidok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
JP5257490B2 (ja) ４，４’−［４−フルオロ−７−（｛４−［４−（３−フルオロ−２−メチルフェニル）ブトキシ］フェニル｝エチニル）−２−メチル−１ｈ−インドール−１，３−ジイル］ジブタン酸、４，４’−［２−メチル−７−（｛４−［４−（ペンタフルオロフェニル）ブトキシ］フェニル｝エチニル）−１ｈ−インドール−１，３−ジイル］ジブタン酸および４，４’−［４−フルオロ−２−メチル−７−（｛４−［４−（２，３，４，６−テトラフルオロフェニル）ブトキシ］フェニル｝エチニル）−１ｈ−インドール−１，３−ジイル］ジブタン酸の新規結晶形
HU198917B (en) Process for producing 2,1-benzothiazepine-2,2-dioxide-5-carboxylic acid derivatives and pharmaceutical compositions containing them
HK1178883B (en) New crystalline forms of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20171119

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20171119